Droperidol Equity 1,25 mg/mL Solution for injection (IV)
PDF Leaflet Revision Date: 17 June 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention and treatment of post-operative nausea and vomiting.
Dosage (summary)
Adults: 0.625 to 1.25 mg IV; Elderly: 0.625 mg IV.
Onset of Action / Duration
Onset: 2-3 mins, Duration: 2-4 hours.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Use in pregnancy is not recommended; excreted in breast milk.
Key Drug Interactions
- QT prolonging agents
- CNS depressants
- Dopaminergic agents
Contraindications
- Hypersensitivity to droperidol
- QT interval prolongation
- Bradycardia
Common side effects
- Drowsiness
- Hypotension
- Cardiac dysrhythmias
Counselling Points
- Avoid driving for 24 hours
- Monitor for drowsiness
- Report any unusual symptoms
Serious warnings
- Risk of QT prolongation
- CNS depression
- Neuroleptic malignant syndrome
Important Disclaimer
The Droperidol Equity 1,25 mg/mL Solution for injection (IV) professional information leaflet below is the property of Equity Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
